Alpine Immune Sciences(ALPN) - 2024 Q1 - Quarterly Results

Cash Position and Runway: As of March 31, 2024, Alpine's cash and investments totaled $362.4 million compared to$368.2 million as of December 31, 2023. The Company anticipates its current cash and investments are sufficient to fund planned operations into 2026. Exhibit 99.1 Alpine Immune Sciences Reports First Quarter 2024 Financial Results SEATTLE, Washington - May 9, 2024 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatme ...